Investors / United States / Illumina Ventures
Illumina Ventures
Venture capital · Foster City, CA, United States · North America
Illumina Ventures is an independently managed venture firm focused on genomics and precision health that supports early-stage companies. It also runs Illumina Ventures Labs, which provides early-stage genomics startups with capital, sequencing, mentorship and equipped lab capabilities.
Invests inHealthcare & BiotechAI & Machine Learning
In its own wordsgenomicsprecision healthlife sciences toolsdiagnosticstherapeuticsdigital health
Your fit with Illumina Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsIllumina Ventures lists 42 checked portfolio companies on its own site and is named in 15 funding rounds, 4 of them as lead. Its most frequent entry is Series B, 33% of the companies with a known first round. Its largest themes are Healthcare & Biotech (77%), AI & Machine Learning (17%) and Cybersecurity (2%). 74% of its companies are based in United States. It invests most often alongside ARCH Venture Partners, ARK Venture Fund and Casdin Capital.
Counts come from funding rounds that name Illumina Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Illumina Ventures' whole history. Rounds on record name 15 companies; its own site lists 42. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 27% |
| Series A | 27% |
| Series B | 33% |
| Growth | 13% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 9 | 3 |
| '26 | 6 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 78th | 42 companies |
| Recent activity | 91th | 7 rounds in 12 months |
| Early stage | 60th | 27% of entries at pre-seed or seed |
| Evidence | 93th | 21% of companies confirmed by a round |
| Sector focus | 93th | 77% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 5 |
| ARK Venture Fund | 3 |
| Casdin Capital | 3 |
| Luminar Ventures | 3 |
| Better Ventures | 2 |
| BrightEdge | 2 |
| Catalio Capital Management | 2 |
| Civilization Ventures | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4095%
- No longer answers00%
- Points to another company25%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 77% | 15% |
| AI & Machine Learning | 17% | 18% |
| Cybersecurity | 2% | 4% |
| Industrial & Manufacturing | 2% | 7% |
| Enterprise Software | 2% | 8% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Illumina Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Illumina Ventures| Date | Company | Stage |
|---|---|---|
| 18 Sept 2026 | Series A | |
| 9 Sept 2026 | Series C+ | |
| 20 Jun 2026 | Series A Led | |
| 10 Jun 2026 | Series B | |
| 15 Apr 2026 | Series B | |
| 12 Jan 2026 | Series B | |
| 11 Dec 2025 | Series B Led | |
| 10 Nov 2025 | Series B |
Round details for Illumina Ventures
Amounts, full round histories and every co-investor in Illumina Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
42 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Actym Therapeutics harnesses the biological intelligence of bacteria to create therapeutics for the treatment of cancer and fibrotic disease. | Healthcare & Biotech | Portfolio page | ||
| Alamar Biosciences develops and provides proteomics products and services, including assays and analysis solutions for various fields such as immunology, neurology, and oncology. | Healthcare & Biotech | Portfolio page | ||
| Arbor Biotechnologies develops novel gene editing treatments for people living with genetic disease | Healthcare & Biotech | Portfolio page | ||
| Arima Genomics is building DNA-based cancer diagnostics that bring sequence and structure together to find more of what drives disease | Healthcare & Biotech | Portfolio page | ||
| Attovia Therapeutics is developing next-generation biotherapeutics for immune-mediated diseases. | Healthcare & Biotech | Apr 2025Series C+ | Page + round | |
| Broken String Biosciences develops gene editing technology and provides bioinformatics products for genome-wide analysis | Healthcare & Biotech | Portfolio page | ||
| Bullseye Biosciences discovers molecules directly in living cells for challenging intracellular targets | Healthcare & Biotech | Portfolio page | ||
| Castle Biosciences develops and provides molecular prognostic and diagnostic tests for various diseases, including skin and eye cancers. | Healthcare & Biotech | Portfolio page | ||
| Cubase Bio develops technologies to transform drug development and disease research by revealing the third dimension of spatial biology. | Healthcare & Biotech | Portfolio page | ||
| DeepSeq.AI uses artificial intelligence for drug discovery | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides blood-based lung cancer screening tests using AI and whole-genome sequencing technology. | Healthcare & Biotech | Portfolio page | ||
| Encoded Therapeutics develops genetic medicines to address the root cause of neurological disorders | Healthcare & Biotech | Sept 2026Series C+ | Funding round | |
| Encoded Therapeutics is developing genetic medicines designed to address the root cause of neurological disorders | Healthcare & Biotech | Portfolio page | ||
| The company develops machine learning foundation models to improve the performance and scalability of quantum computers. | AI & Machine LearningCybersecurity | Oct 2025Seed | Funding round | |
| Fuze Health provides comprehensive care services, including pharmacy solutions, clinical services, and data technology, to patients and healthcare partners. | Healthcare & BiotechHealthcare & Biotech | Portfolio page | ||
| Genome Medical provides genetic services and counseling to patients and families with rare diseases | Healthcare & Biotech | Portfolio page | ||
| Hepta is decoding tissue-level biology from blood, starting with metabolic dysfunction-associated steatohepatitis (MASH) | Healthcare & Biotech | Portfolio page | ||
| HEPTA Medical develops a microwave ablation platform for medical procedures | Healthcare & Biotech | Nov 2025Seed | Funding round | |
| Iambic Therapeutics develops medicines using artificial intelligence and molecular technologies | Healthcare & Biotech | Nov 2025Series B | Page + round | |
| Infinity Bio decodes the antibody reactome to transform immunology research | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- illuminaventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 15 Apr 2025
- Companies checked
- 42
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Illumina Ventures' profile as data
Pull Illumina Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/illuminaventures.com
# also
GET /v1/firms/illuminaventures.com/portfolio
GET /v1/firms/illuminaventures.com/coinvestors
GET /v1/firms/illuminaventures.com/news